Neurogene Inc. (NGNE)
Neurogene Inc. (NGNE) from its SEC filings: 2025 revenue $0 (-100% vs the year before), free cash flow -$78.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $0 |
| Revenue growth | -100% |
| Net income | -$90.4 million |
| Free cash flow | -$78.4 million |
| Diluted EPS | $-4.24 |
| Cash | $112.5 million |
| Share count, 1 year | +40% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-11-02. Education only, not financial advice.